1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 4, 2013, Pages 603-613

  Prinz, Michaela ^a   Parlar, Sülünay ^b   Bayraktar, Gülşah ^b   Alptüzün, Vildan ^b   Erciyas, Ercin ^b   Fallarero, Adyary ^c   Karlsson, Daniela ^c   Vuorela, Pia ^c   Burek, Malgorzata ^a   Förster, Carola ^a   Turunc, Ezgi ^b   Armagan, Guliz ^b   Yalcin, Ayfer ^b   Schiller, Carola ^d   Leuner, Kristina ^d   Krug, Manuel ^a   Sotriffer, Christoph A ^a   Holzgrabe, Ulrike ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b EGE UNIVERSITY   (Turkey)

^c ÅBO AKADEMI UNIVERSITY   (Finland)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Acetylcholinesterase (AChE); Alzheimer; Amyloid ; Butyrylcholinesterase (BuChE); Thioflavin T

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; HYDRAZONE DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; IC 50; LIPID PEROXIDATION; LIPOPHILICITY; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; STRUCTURE ACTIVITY RELATION;

EID: 84879480510     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.04.024     Document Type: Article

References (78)

1. Alptuzun, V., Kapkova, P., Baumann, K., Erciyas, E., Holzgrabe, U., 2003. Synthesis and biological activity of pyridinium-type acetylcholinesterase inhibitors. J. Pharm. Pharmacol. 55, 1397-1404. (Pubitemid 37321383)
2. Alptuzun, V., Prinz, M., Horr, V., Scheiber, J., Radacki, K., Fallarero, A., Vuorela, P., Engels, B., Braunschweig, H., Erciyas, E., Holzgrabe, U., 2010. Interaction of (benzylidene-hydrazono)-1,4-dihydropyridines with beta-amyloid, acetylcholine, and butyrylcholine esterases. Bioorg. Med. Chem. 18, 2049-2059.
3. Alzheimer, A., 1907. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Zeitung Psychiatr. Psych.-Gerichtl. Med. 64, 146-148.
4. Alzheimer's Association, 2011. Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia.
5. a determination of water-insoluble drugs in organic solvent-water mixtures. J. Pharmaceut. Biomed. Anal. 20, 631-641. (Pubitemid 29245964)
6. Aydin, A., Akkurt, M., Alptuzun, V., Buyukgungor, O., Holzgrabe, U., Radacki, K., 2010. 4-[(2E)-2-(4-Chlorobenzylidene)hydrazinylidene]-1-methyl-1,4- dihydropyridine monohydrate. Acta Cryst. Sec. E 66, o1324-o1325.
7. Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., Jones, E., 2011. Alzheimer's disease. Lancet 377, 1019-1031.
8. Bard, F., Cannon, C., Barbour, R., Burke, R.L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Lieberburg, I., Motter, R., Nguyen, M., Soriano, F., Vasquez, N., Weiss, K., Welch, B., Seubert, P., Schenk, D., Yednock, T., 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919. (Pubitemid 30644751)
9. Benzi, G., Moretti, A., 1995. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol. Aging 16, 661-674.
10. Berg, S., Bergh, M., Hellberg, S., Hogdin, K., Lo-Alfredsson, Y., Soderman, P., von Berg, S., Weigelt, T., Ormo, M., Xue, Y., Tucker, J., Neelissen, J., Jerning, E., Nilsson, Y., Bhat, R., 2012. Discovery of novel potent and highly selective glycogen synthase kinase-3beta (GSK3beta) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. J. Med. Chem. 55, 9107-9119.
11. Brunhofer, G., Fallarero, A., Karlsson, D., Batista-Gonzalez, A., Shinde, P., Gopi Mohan, C., Vuorela, P., 2012. Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine. Bioorg. Med. Chem. 20, 6669-6679.
12. Campagna, F., Catto, M., Purgatorio, R., Altomare, C.D., Carotti, A., De Stradis, A., Palazzo, G., 2011. Synthesis and biophysical evaluation of arylhydrazono-1H-2-indolinones as β-amyloid aggregation inhibitors. Eur. J. Med. Chem. 46, 275-284.
13. Catto, M., Berezin, A.A., Lo Re, D., Loizou, G., Demetriades, M., De Stradis, A., Campagna, F., Koutentis, P.A., Carotti, A., 2012. Design, synthesis and biological evaluation of benzo[e][1,2,4]triazin-7(1H)-one and [1,2,4]-triazino[5,6,1-jk]carbazol-6-one derivatives as dual inhibitors of beta-amyloid aggregation and acetyl/butyryl cholinesterase. Eur. J. Med. Chem. 58, 84-97.
14. Cavalli, A., Bolognesi, M.L., 2012. Multitargeted Drugs for Treatment of Alzheimer's Disease, Polypharmacology in Drug Discovery. John Wiley & Sons Inc., pp. 441-458.
15. Cavalli, A., Bolognesi, M.L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., Melchiorre, C., 2008. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem 51, 347-372. (Pubitemid 351252260)
16. Christen, Y., 2000. Oxidative stress and Alzheimer disease. Am. J. Clin. Nut. 71, 621s-629s. (Pubitemid 30061247)
17. a prediction and ADME profiling. Chem. Biodiv. 6, 1812-1821.
18. De Felice, F.G., Vieira, M.N., Saraiva, L.M., Figueroa-Villar, J.D., Garcia-Abreu, J., Liu, R., Chang, L., Klein, W.L., Ferreira, S.T., 2004. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB 18, 1366-1372. (Pubitemid 39150351)
19. Decker, M., Holzgrabe, U., 2012. M1 muscarinic acetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimers disease. Med Chem Comm 3, 752-762.
20. Dermaut, B., Kumar-Singh, S., Rademakers, R., Theuns, J., Cruts, M., Van Broeckhoven, C., 2005. Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum. Trends Genet. 21, 664-672. (Pubitemid 41608689)
21. Deutsche Alzheimer Gesellschaft, 2010. Factsheet "Die Epidemiologie der Demenz".
22. Douglas, A.W., Fisher, M.H., Fishinger, J.J., Gund, P., Harris, E.E., Olson, G., Patchett, A.A., Ruyle, W.V., 1977. Anticoccidial 1-substituted 4(1H)-pyridinone hydrazones. J. Med. Chem. 20, 939-943.
23. Draper, H.H., Hadley, M., 1990. Malondialdehyde determination as index of lipidperoxidation. Method Enzymol. 186, 421-431.
24. Driver, A.S., Kodavanti, P.R., Mundy, W.R., 2000. Age-related changes in reactive oxygen species production in rat brain homogenates. Neurotoxicol. Teratol. 22, 175-181. (Pubitemid 30176073)
25. Dumont, M., Beal, M.F., 2011. Neuroprotective strategies involving ROS in Alzheimer disease. Free Rad. Bio. Med. 51, 1014-1026.
26. Ellman, G.L., Courtney, K.D., Andres Jr., V., Feather-Stone, R.M., 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 88-95.
27. Fagan, 2002. Human and murine ApoE markedly alters abeta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9, 305-318. (Pubitemid 34442079)
28. Fallarero, A., Oinonen, P., Gupta, S., Blom, P., Galkin, A., Mohan, C.G., Vuorela, P.M., 2008. Inhibition of acetylcholinesterase by coumarins: the case of coumarin 106. Pharmacol. Res. 58, 215-221.
29. Fernández-Bachiller, M.I., Pérez, C., Monjas, L., Rademann, J., Rodríguez-Franco, M.I., 2012. New Tacrine-4-Oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties. J. Med. Chem 55, 1303-1317.
30. Fisher, A., 2012. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J. Neurochem. 120, 22-33.
31. Fonseca, A.C.R.G., Resende, R., Oliveira, C.R., Pereira, C.M.F., 2010. Cholesterol and statins in Alzheimer's disease: current controversies. Exp. Neurol. 223, 282-293.
32. Förster, C., Silwedel, C., Golenhofen, N., Burek, M., Kietz, S., Mankertz, J., Drenckhahn, D., 2005. Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system. J. Physiol. 565, 475-486. (Pubitemid 40879596)
33. Gazit, E., 2005. Mechanisms of amyloid fibril self-assembly and inhibition. FEBS 272, 5971-5978.
34. Ghosh, A.K., Brindisi, M., Tang, J., 2012. Developing beta-secretase inhibitors for treatment of Alzheimer's disease. J. Neurochem. 120, 71-83.
35. Goldsbury, C.S., Wirtz, S., Müller, S.A., Sunderji, S., Wicki, P., Aebi, U., Frey, P., 2000. Studies on the in vitro assembly of aβ 1-40: implications for the search for Aβ fibril formation inhibitors. J. Struct. Biol. 130, 217-231.
36. Goodwin, J.T., Clark, D.E., 2005. In silico predictions of blood-brain barrier penetration: considerations to "keep in mind". J. Pharmacol. Exp. Ther. 315, 477-483. (Pubitemid 41500710)
37. Graeber, M.B., Kösel, S., Egensperger, R., Banati, R.B., Müller, U., Bise, K., Hoff, P., Möller, H.J., Fujisawa, K., Mehraein, P., 1997. Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. Neurogenetics 1, 73-80. (Pubitemid 127709612)
38. Gregor, V.E., Emmerling, M.R., Lee, C., Moore, C.J., 1992. The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex®) derivaties. Bioorg. Med. Chem. Lett. 2, 861-864.
39. Greig, N.H., Utsuki, T., Ingram, D.K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.S., Mamczarz, J., Holloway, H.W., Giordano, T., Chen, D., Furukawa, K., Sambamurti, K., Brossi, A., Lahiri, D.K., 2005. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sc. USA 102, 17213-17218. (Pubitemid 41692709)
40. Hanger, D.P., Hughes, K., Woodgett, J.R., Brion, J.-P., Anderton, B.H., 1992. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosc. Lett. 147, 58-62.
41. Hardy, J., Selkoe, D.J., 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
42. Hebert, L.E., Beckett, L.A., Scherr, P.A., Evans, D.A., 2001. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. AD Ass. Disorders 15, 169-173. (Pubitemid 33117032)
43. Hodge, A.S., Humphrey, D.R., Rosenberry, T.L., 1992. Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol. Pharmacol. 41, 937-942. (Pubitemid 23023339)
44. Huang, Y., Mucke, L., 2012. Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.
45. Imbimbo, B.P., 2009. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. Exp. Op. Invest. Drugs 18, 1147-1168.
46. Ingkaninan, K., de Best, C.M., van der Heijden, R., Hofte, A.J.P., Karabatak, B., Irth, H., Tjaden, U.R., van der Greef, J., Verpoorte, R., 2000. High-performance liquid chromatography with on-line coupled UV, mass spectrometric and biochemical detection for identification of acetylcholinesterase inhibitors from natural products. J. Chromatogr. 872, 61-73. (Pubitemid 30122885)
47. Kapková, P., Stiefl, N., Sürig, U., Engels, B., Baumann, K., Holzgrabe, U., 2003. Synthesis, biological activity, and docking studies of new acetylcholinesterase inhibitors of the bispyridinium type. Arch. Pharm. 336, 523-540. (Pubitemid 38005047)
48. Karlsson, D., Fallarero, A., Brunhofer, G., Guzik, P., Prinz, M., Holzgrabe, U., Erker, T., Vuorela, P., 2012. Identification and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fibril formation. Eur. J. Pharm. Sci. 45, 169-183.
49. Kelder, J., Grootenhuis, P.D.J., Bayada, D.M., Delbressine, L.P.C., Ploemen, J.P., 1999. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16, 1514-1519. (Pubitemid 29510546)
50. Landi, F., Cesari, M., Onder, G., Russo, A., Torre, S., Bernabei, R., Group, T.S.-H.S., 2003. Non-steroidal anti-inflammatory drug (NSAID) use and alzheimer disease in community-dwelling elderly patients. Am. J. Geriatric Psychiat. 11, 179-185. (Pubitemid 36254191)
51. Leeson, P.D., Oprea, T.I., 2012. Drug-like physicochemical properties. In: Livingstone, D.J., Davis, A.M. (Eds.), Drug Design Strategies: Quantitative Approaches, RSC publisher, pp. 35-59.
52. Leuner, K., Muller, W.E., Reichert, A.S., 2012a. From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. J. Mol. Neurobiol. 46, 186-193.
53. Leuner, K., Schutt, T., Kurz, C., Eckert, S.H., Schiller, C., Occhipinti, A., Mai, S., Jendrach, M., Eckert, G.P., Kruse, S.E., Palmiter, R.D., Brandt, U., Drose, S., Wittig, I., Willem, M., Haass, C., Reichert, A.S., Muller, W.E., 2012b. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid. Redox Signal 16, 1421-1433.
54. Levin, V.A., 1980. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem 23, 682-684. (Pubitemid 11237830)
55. Levine, H., 1993. Thioflavine T interaction with synthetic Alzheimer's disease βamyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2, 404-410.
56. Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
57. Mahley, R.W., Weisgraber, K.H., Huang, Y., 2006. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sc. USA 103, 5644-5651.
58. Mann, F.G., Prior, A.F., Willcox, T.J., 1959. The structure and properties of certain polycyclic indolo-and quinolino-derivatives. Part XIII. The cyclisation of certain 4-pyridyl-and 4-quinolyl-hydrazones. J. Chem. Soc. 773, 3830-3834.
59. Mary, A., Renko, D.Z., Guillou, C., Thal, C., 1998. Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bisinteracting ligands in the galanthamine series. Bioorg. Med. Chem. 6, 1835-1850. (Pubitemid 28524237)
60. Massoud, F., Gauthier, S., 2010. Update on the pharmacological treatment of Alzheimer's disease. Curr. Neuropharmacol. 8, 69-80.
61. McKenna, M.T., Proctor, G.R., Young, L.C., Harvey, A.L., 1997. Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors. J. Med. Chem. 40, 3516-3523. (Pubitemid 27465083)
62. Merrifield, R.B., 1963. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85, 2149-2154.
63. a prediction method using grid molecular interaction fields. J. Chem. Inf. Modeling 47, 2172-2181. (Pubitemid 350275083)
64. Morgan, D., 2011. Immunotherapy for Alzheimer's disease. J. Intern. Med. 269, 54-63.
65. Nicolet, Y., Lockridge, O., Masson, P., Fontecilla-Camps, J.C., Nachon, F., 2003. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 278, 41141-41147. (Pubitemid 37280939)
66. Nitsch, R.M., Deng, A., Wurtman, R.J., Growdon, J.H., 1997. Metabotropic glutamate receptor subtype mGluR1α stimulates the secretion of the amyloid β-protein precursor ectodomain. J. Neurochem. 69, 704-712. (Pubitemid 27327973)
67. Olgen, S., Kilic, Z., Ada, A.O., Coban, T., 2007. Synthesis and evaluation of novel N-H and N-substituted indole-2-and 3-carboxamide derivatives as antioxidants agents. J. Enzyme Inhib. Med. Chem. 22, 457-462. (Pubitemid 47225709)
68. Postina, R., 2012. Activation of alpha-secretase cleavage. J. Neurochem. 120, 46-54.
69. Radic, Z., Pickering, N.A., Vellom, D.C., Camp, S., Taylor, P., 1993. Three distinct domains in the cholinesterase molecule confer selectivity for acetyl-and butyrylcholinesterase inhibitors. Biochem. 32, 12074-12084. (Pubitemid 23353646)
70. Scarpini, E., Schelterns, P., Feldman, H., 2003. Treatment of Alzheimer's disease; current status and new perspectives. Lancet Neurol. 2, 539-547. (Pubitemid 36994993)
71. Schulz, K.L., Eckert, A., Rhein, V., Mai, S., Haase, W., Reichert, A.S., Jendrach, M., Muller, W.E., Leuner, K., 2012. A new link to mitochondrial impairment in tauopathies. J. Mol. Neurobiol. 46, 205-216.
72. Solomon, B., Koppel, R., Hanan, E., Katzav, T., 1996. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl. Acad. Sc. USA 93, 452-455. (Pubitemid 26038175)
73. Tjernberg, L.O., Callaway, D.J.E., Tjernberg, A., Hahne, S., Lilliehöök, C., Terenius, L., Thyberg, J., Nordstedt, C., 1999. A molecular model of Alzheimer amyloid βpeptide fibril formation. J. Biol. Chem. 274, 12619-12625.
74. Vlad, S.C., Miller, D.R., Kowall, N.W., Felson, D.T., 2008. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70, 1672-1677. (Pubitemid 351644133)
75. 2+ overload. Bioorg. Med. Chem. 20, 6513-6522.
76. Wellings, D.A., Atherton, E., 1997. Standard Fmoc protocols. In: Gregg, B.F. (Ed.), Methods Enzymol. Academic Press, pp. 44-67. (Pubitemid 27467242)
77. Wolfe, M.S., 2012. Secretase inhibitors and modulators for Alzheimer's disease. J. Neurochem. 120, 89-98.
78. Yang, F., Lim, G.P., Begum, A.N., Ubeda, O.J., Simmons, M.R., Ambegaokar, S.S., Chen, P.P., Kayed, R., Glabe, C.G., Frautschy, S.A., Cole, G.M., 2005. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901. (Pubitemid 40280072)